共 19 条
- [1] Pre-Clinical Efficacy of CDK7 Inhibitor-Based Combinations in Cellular Models of Advanced Myeloproliferative Neoplasms (MPN) Transformed to AMLBLOOD, 2023, 142Fiskus, Warren C.Bose, PrithvirajMasarova, LuciaMill, Christopher PeterBirdwell, ChristineDavis, JohnDas, KaberiHou, HanxiManshouri, TaghiPhilip, KevinAlhamadani, NoorMatthews, AliciaLoghavi, SanamBhalla, Kapil N.
- [2] Preclinical efficacy of CDK7 inhibitor-based combinations against myeloproliferative neoplasms transformed to AMLBLOOD, 2025, 145 (06) : 612 - 624Fiskus, WarrenMill, Christopher P.Bose, PrithvirajMasarova, LuciaPemmaraju, NaveenDunbar, AndrewBirdwell, Christine E.Davis, John A.Das, KaberiHou, HanxiManshouri, TaghiJain, AntrixMalovannaya, AnnaPhilip, KevinAlhamadani, NoorMatthews, AliciaLin, KatieFlores, Lauren B.Loghavi, SanamDinardo, CourtneySu, XiaopingRampal, Raajit K.Bhalla, Kapil N.
- [3] Efficacy of CDK9 inhibitor-based combinations as therapy for post-myeloproliferative neoplasm (MPN) secondary (s) AMLCANCER RESEARCH, 2019, 79 (13)Saenz, Dyana T.Fiskus, Warren C.Manshouri, TaghiMill, Christopher P.Khoury, Joseph D.Verstovsek, SrdanBhalla, Kapil N.
- [4] Preclinical Studies Demonstrating Efficacy of Tasquinimod in Models of Advanced Myeloproliferative Neoplasm (MPN) in Blastic PhaseBLOOD, 2023, 142Fiskus, Warren C.Masarova, LuciaMill, Christopher PeterBirdwell, ChristineDas, KaberiDavis, JohnHou, HanxiAlhamadani, NoorPhilip, KevinMatthews, AliciaManshouri, TaghiKadia, Tapan M.DiNardo, Courtney D.Bose, PrithvirajPemmaraju, NaveenLoghavi, SanamTorngren, MarieBhalla, Kapil N.
- [5] SY5609, a Potent and Selective CDK7 Inhibitor, Potentiates BTK Inhibitor Activity in Mantle Cell Lymphoma Preclinical ModelsBLOOD, 2021, 138Johannessen, LivHenry, SusanSawant, PriyankaD'Ippolito, AnthonyKe, NanLefkowitz, ArielEaton, MatthewDworakowski, WojciechRosario, MariaHodgson, Graeme
- [6] Activity of SY-5609, an oral, noncovalent, potent, and selective CDK7 inhibitor, in preclinical models of colorectal cancer.JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)Johannessen, LivKe, NanSawant, PriyankaDworakowski, WojciechD'Ippolito, AnthonyHu, ShanhuRajagopal, NishaEaton, MatthewHodgson, Graeme
- [7] Potent efficacy of MCL-1 inhibitor-based therapies in preclinical models of mantle cell lymphomaONCOGENE, 2020, 39 (09) : 2009 - 2023Dengler, Michael A.Teh, Charis E.Thijssen, RachelGangoda, LahiruLan, PingHerold, Marco J.Gray, Daniel H.Kelly, Gemma L.Roberts, Andrew W.Adams, Jerry M.
- [8] Potent efficacy of MCL-1 inhibitor-based therapies in preclinical models of mantle cell lymphomaOncogene, 2020, 39 : 2009 - 2023Michael A. DenglerCharis E. TehRachel ThijssenLahiru GangodaPing LanMarco J. HeroldDaniel H. GrayGemma L. KellyAndrew W. RobertsJerry M. Adams
- [9] Preclinical evaluation of KRLS-017, a potent, highly selective and reversible CDK7 inhibitor with broad antitumor effect in preclinical models, in preparation for a Phase 1 clinical trial in advanced solid tumor malignanciesCANCER RESEARCH, 2024, 84 (06)Hannah, Alison L.Ritland, SteveSteele, ThomasSmith, StevenRam, AshwinSlingsby, B. T.Dhingra, KapilChrisman, JamesDua, RajeshTokunaga, YasunoriKono, ShigeyukiAga, Yasuhiro
- [10] SY-1365, a potent and selective CDK7 inhibitor, exhibits promising anti-tumor activity in multiple preclinical models of aggressive solid tumorsCANCER RESEARCH, 2017, 77Hu, ShanhuKe, NanRen, YixuanMiljovska, SofijaRajagopal, NishaMcKeown, MichaelOrlando, DavidSprott, KevinChoi, Yoon J.Olson, EricFritz, Christian C.